A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer


The purpose of this study is to learn the effects, good or bad, of several possible study treatments for EndoCA that are selected based on genetic markers that can be found in these tumors.

I'm interested

18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy
Exclusion Criteria:

• primary invasive ovarian or cervical cancer occurring with this cancer
• other cancer occurring in the past 5 years
• active or history of autoimmune disease or immune deficiency
• history of cardiac, respiratory or neurological conditions (study staff will review)

Drug: Abemaciclib, Drug: Atezolizumab - 21 Day Cycle, Drug: Atezolizumab - 28 Day Cycle, Drug: Bevacizumab, Drug: Giredestrant, Drug: Inavolisib, Drug: Ipatasertib, Drug: Letrozole, Drug: Talazoparib, Drug: Tiragolumab, Drug: Trastuzumab emtansine

Cancer, Women's Health

Clinics and Surgery Center (CSC), EndoCA, Endometrial Cancer

Britt Erickson -
Britt Erickson
Phase 1/Phase 2
See this study on